The Combined Estrogen-Progestin Transdermal Birth Control Patch is NOT Safe for Breastfeeding
Combined hormonal contraceptives, including the transdermal patch, are contraindicated during the first 6 weeks postpartum due to thromboembolism risk, and progestin-only methods should be used instead during breastfeeding. 1
Critical Timing Considerations
The transdermal contraceptive patch contains both estrogen and progestin, which places it in the category of combined hormonal contraceptives (CHC). The French Society of Endocrinology guidelines explicitly state that combined hormonal contraceptives are prohibited during the six weeks following childbirth due to the risk of postpartum thromboembolism 1. During this period and throughout breastfeeding, a progestin-only method is the only acceptable hormonal contraceptive option.
Why Combined Methods Are Problematic During Breastfeeding
Thromboembolism Risk
The postpartum period carries an inherently elevated risk of venous thromboembolism (VTE). The transdermal patch specifically has been identified by the FDA as having 1.6 times higher estrogen exposure than low-dose combined oral contraceptives and carries a potential increased risk of venous thromboembolism 2. This elevated estrogen exposure makes the patch particularly concerning in the already high-risk postpartum period.
Milk Supply Concerns
While recent research suggests minimal transfer of ethinylestradiol into breast milk with modern low-dose formulations 3, the primary concern is not infant exposure but rather the potential negative impact on milk production. Combined hormonal contraception containing estrogen has been associated with concerns about decreased milk supply, though the evidence quality is limited 4.
Safer Alternatives for Breastfeeding Women
Preferred Options (in order of effectiveness):
Progestin Implants - The single-rod etonogestrel implant is highly effective (<1% failure rate) and studies have found no effects on breastfeeding performance or infant health and growth 2. Can be inserted immediately postpartum while still in the hospital.
IUDs - Both copper and levonorgestrel-releasing IUDs have <1% failure rates and are safe during breastfeeding 2, 5.
Progestin-Only Pills - Safe during breastfeeding, though require strict daily adherence (5-8% typical failure rate) 2, 5.
DMPA Injection - Safe for breastfeeding women (3% failure rate), though should be avoided in those at risk for osteoporosis 5.
Clinical Algorithm for Postpartum Contraception
Weeks 0-6 postpartum:
- Progestin-only methods ONLY
- Avoid ALL combined hormonal contraceptives including the patch
After 6 weeks postpartum:
- If breastfeeding continues: Progestin-only methods remain preferred
- If not breastfeeding and no other contraindications: Combined methods may be considered
Special consideration: The 2020 ACR guidelines for women with systemic lupus erythematosus specifically recommend avoiding the estrogen patch even in those with low disease activity 5, highlighting additional safety concerns with this delivery method.
Common Pitfall to Avoid
Do not assume that transdermal delivery is safer than oral combined contraceptives during breastfeeding. The patch actually delivers higher total estrogen exposure than many oral contraceptives 2, 6, making it a particularly poor choice for postpartum women. The convenience of weekly application does not outweigh the safety concerns during lactation.
Bottom line: Counsel breastfeeding patients toward long-acting reversible contraception (implants or IUDs) or other progestin-only methods. The transdermal patch should be reserved for non-breastfeeding women beyond 6 weeks postpartum who have no other contraindications to combined hormonal contraception.